Life Science Compliance Update

As life science compliance professionals know, it is important to monitor what the HHS OIG focuses on. This article reviews the…

The topic of ‘company culture’ is certainly not new, but it continually emerges as a hot topic within regulatory circles. An…

The distinct split between the Second and Fifth Circuit Courts’ interpretation as to when whistleblower protections are allowed…

With the new administration, there appears to be a renewed commitment to enforcing anti-kickback rules against healthcare…

In the September issue of the Life Science Compliance Update, the authors discussed the new Ohio drug distribution verification…

Over the past two decades, the role that patients play in their health care has dramatically shifted. As a result, there is an…

As opposition to and concern about the activities of drug manufacturers continue to mount, increasingly states, and even cities,…

The concern of misbranded products leading to patient harm and potential fraud is inarguable. The FDA has held a long-standing…

In a nearly decade long lawsuit involving the dialysis company Fresenius, and allegations that the company violated the False…

It has been over one-year since the US Department of Justice has launched its pilot program aimed to incentivize companies to…